Kyowa Kirin Co., Ltd. (KYKOF)
OTCMKTS
· Delayed Price · Currency is USD
14.75
0.00 (0.00%)
At close: Apr 11, 2025
Kyowa Kirin Revenue
In the year 2024, Kyowa Kirin had annual revenue of 495.56B JPY with 12.06% growth. Kyowa Kirin had revenue of 132.76B in the quarter ending December 31, 2024, a decrease of -2.51%.
Revenue
495.56B JPY
Revenue Growth
+12.06%
P/S Ratio
2.54
Revenue / Employee
87.42M JPY
Employees
5,669
Market Cap
7.99B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 495.56B | 53.33B | 12.06% |
| Dec 31, 2023 | 442.23B | 43.86B | 11.01% |
| Dec 31, 2022 | 398.37B | 46.13B | 13.09% |
| Dec 31, 2021 | 352.25B | 33.89B | 10.65% |
| Dec 31, 2020 | 318.35B | 12.53B | 4.10% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 43.26M |
Kyowa Kirin News
- 7 weeks ago - Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Phase 3 Results for Rocatinlimab in Atopic ... - GuruFocus
- 2 months ago - Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025 - PRNewsWire
- 2 months ago - Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies - Benzinga
- 3 months ago - Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe - Business Wire
- 3 months ago - AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform - GlobeNewsWire
- 4 months ago - Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies - Business Wire
- 5 months ago - Kura stock slides 17% on Kyowa Kirin deal for ziftomenib - Seeking Alpha
- 5 months ago - Kura Oncology to partner with Kyowa Kirin for blood cancer therapy - Reuters